DCAT Value Chain Insights Podcast: Recent Episodes
DCAT
The DCAT Value Chain Insights Podcast, presented by the Drug, Chemical & Associated Technologies Association, presents specially selected articles from our website (DCATvci.org) that feature in-depth analysis on the issues impacting the business of pharmaceutical development and manufacturing.
What are some key trends and issues arising in parenteral drug development and manufacturing? From more complex molecules and modalities and sterile drug-product capacity market shifts, DCAT Value Chain Insights takes an inside look. For the text version of this article visitdcatvci.org.
Key topics: (see Chapter Markers in drop down menu in audio player above)
- Major trends in parenteral drug development
- Long peptides in NDAs and BLAs
- New complex modalities
- Sterile drug-product capacity market shifts
- Complex sterile injectables
- Regulatory issues
- Digitalization and automation
Podcast Sponsor: Vetter Pharma International GmbH
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show
Support the show
As 2023 comes to a close, what were the largest mergers and acquisitions and expansions made by CDMOs/CMOs in 2023? DCAT Value Chain Insights looks at which companies topped the headlines this year and the leading moves they made. For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers in drop down menu in audio player above)
- Baxter
- Samsung Biologics
- Lotte Biologics
- Fujifilm Diosynth Biotechnologies
- Lonza
- Cambrex
- Expansions in peptides, oligonucleotides
- Bachem
- Agilent Technologies
- WuXi STA
- CordenPharma
- Ajinomoto
- Bain’s acquisition of F.I.S.
- eureKING
- New CDMOs enter the market
- Bridgewest Group
- SynCrest
- NewBiologix
- Ascend Gene & Cell Therapies
Podcast Sponsor: Vetter Pharma International GmbH
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show
Support the show
As we near the mid-year mark, what have been the key moves—mergers and acquisitions, expansions, and new CDMOs entering the market—thus far in 2023? DCAT Value Chain Insights takes an inside look on what is on the industry’s radar. For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers in drop down menu in audio player above)
- Baxter
- Large-scale biomanufacturing expansions continue
- Samsung Biologics
- Lotte Biologics
- Fujifilm Diosynth Biotechnologies
- Lonza
- WuXi Biologics
- Expansions in Peptides and Oligonucleotides Ramp Up
- Bachem
- Agilent Technologies
- WuXi STA
- CordenPharma
- New CDMOs Enter the Market
- eureKING
- NewBiologix
- Ascend Gene & Cell Therapies
Podcast Sponsor: Vetter Pharma International GmbH
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show
Support the show
Support the show
The European Commission has issued its long-awaited proposal to reform pharmaceutical legislation in the EU, the first major overhaul in 20 years, which includes new requirements to address drug shortages and secure supply chains. For the text version of this article visit dcatvci.org. Key topics: (see Chapter Markers in drop down menu in audio player above)
- Proposed reforms
- Security of supply and supply-chain reforms
- Specific proposals
Podcast Sponsor: BIOVECTRA
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show
Support the show
Increased demand in biologic-based drug development is a key factor driving demand for parenteral drug manufacturing. What are key trends and expansions by CDMO/CMOs in parenteral drug manufacturing? DCAT Value Chain Insights rounds up the latest developments among CDMO/CMOs. For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers in drop down menu in audio player above)
- Recent expansion projects
- Baxter BioPharma Solutions
- Vetter
- Recipharm
- WuXi STA
- Jubilant HollisterStier
- PCI Pharma Services
- Grand River Aseptic Manufacturing
- Catalent
- Thermo Fisher Scientific
- Lonza
- Carbogen Amcis
- Alcami
- Delpharm
- Fareva
- WuXi Biologics
- IDT Biologika
- Emergent CDMO
- BSP Pharmaceuticals
- Aenova
- Samsung Biologics
- Ajinomoto Bio-Pharma Services
- Selkirk Pharma
- INCOG BioPharma Services
- ten23 health
- Berkshire Sterile Manufacturing
Sponsor: Vetter Pharma International GmbH
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show
Support the show
What are noteworthy trends in drug delivery and drug-product development in key dosage forms: solid dosage and parenteral drugs? A look at key technology advances and recent new drug approvals. For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers in drop down menu in audio player above)
- Recent trends: new drug approvals
- Technology advances
- Enable Injections’ on-body subcutaneous drug-delivery system
- Lilly’s and Triastek’s pact for 3-D printing for oral drug delivery
- Multifunctional wireless robots in drug delivery
- Advances in implantable devices for drug delivery
Sponsor: Vetter Pharma International GmbH
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show
Support the show
Growth in the oncology drug market continues to spur demand for high-potency API manufacturing. Which CDMOs/CMOs are expanding? DCAT Value Chain Insights rounds up the latest investments. For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers in drop down menu in audio player above)
- A roundup of recent investments in HPAPI manufacturing
- WuXi STA
- MilliporeSigma
- Piramal Pharma Solutions
- Cambrex
- HAS Healthcare Advanced Synthesis
- AGC Fine Chemicals
- Lonza
- Carbogen Amcis
- Sterling Pharma Solutions
- Ajinomoto Bio-Pharma Services
- Novasep
- Olon
- Cerbios-Pharma
- Formosa Laboratories
- Sai Life Sciences
- BSP Pharmaceuticals
- Seqens
- CordenPharma
Sponsor: BIOVECTRA
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show
Support the show
A newly released DCAT benchmarking study examines the targets and progress made by bio/pharma companies and suppliers in reaching their sustainability goals. For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers in drop down menu in audio player above)
- Sustainability and the bio/pharma supply chain
- Key finding: External stakeholders drive efforts
- Key finding: Supply-chain sustainability lags internal efforts
- Key finding: Measuring achievement a major challenge
- Key finding: Factoring sustainability into purchasing decisions
- Concluding thoughts
Sponsor: LGM Pharma
Links:
- Subscribe to our e-newsletter at www.dcatvci.org
- Follow us on Twitter @DCATvci
- Support the show
Support the show (https://dcat.org/MemberApplication.htm)
Capital investments are ramping up in biomanufacturing, which continues to be an active area for CDMOs/CMOs in both traditional biologics and new modalities. Which companies are expanding? For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers in drop down menu in audio player above)
- A roundup of expansion activity
- Fujifilm Diosynth Biotechnologies
- Samsung Biologics
- Lonza
- Boehringer Ingelheim
- Thermo Fisher Scientific
- Catalent
- WuXi Biologics
Sponsor: BIOVECTRA
Links:Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show
Support the show (https://dcat.org/MemberApplication.htm)
A DCAT Week program brings together leading Bio/Pharma executives to offer their perspectives on how Bio/Pharma companies and their suppliers are adjusting supply practices now and in the near term. For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- Supply-chain challenges and solutions (1:13)
Sponsor: LGM Pharma
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show
Support the show (https://dcat.org/MemberApplication.htm)
Parenteral drugs have accounted for between 40% and 50% of new drug approvals over the past five years. CDMOs/CMOs continue to expand. For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers in drop down menu in audio player above)
- Active area of investment (1:13)
- Baxter BioPharma Solutions (1:25)
- PCI Pharma Services (2:07)
- Alcami (3:22)
- Catalent (4:31)
- Vetter (5:47)
- Thermo Fisher Scientific (6:41)
- Grand River Aseptic Manufacturing (7:35)
- Lonza (9:12)
- Curia (9:50)
- Jubilant HollisterStier (10:22)
- Carbogen Amcis (10:53)
- Fareva (11:46)
- BSP Pharmaceuticals (12:43)
- Recipharm (13:33)
- Aenova (15:01)
- Wuxi Biologics (15:42)
- Samsung Biologics (16:08)
- Ajinomoto Bio-Pharma Services (16:44)
- Selkirk Pharma (17:07)
Sponsor: Vetter Pharma International GmbH
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show (https://dcat.org/MemberApplication.htm)
Support the show (https://dcat.org/MemberApplication.htm)
Escalating energy prices are impacting global manufacturing and supply chains. In the EU, leaders are proposing measures to alleviate pricing pressures. What’s the plan?
Key topics: (see Chapter Markers)
- Economic recovery brings pricing pressures
- Rising energy costs and the bio/pharma manufacturing value chain
- Rising energy costs: call for action in the EU
- Ripple effect throughout industrial supply chains
- Actions proposed by the European Commission
- Proposals for energy-price relief
Sponsor: LGM Pharma
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show (https://dcat.org/MemberApplication.htm)
Which modality, small molecules or biologics, leads among the top-selling products? A look at the top-selling products industry-wide and blockbusters from select leading bio/pharma companies provides the answer. For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- Modality of top-selling products
- New drug approvals: small molecules versus biologics
- Potential blockbusters: small molecules and biologics
- Biogen’s and Eisai’s aducanumab
- Argenx’s efgartigimod
- Bristol-Myers Squibb’s mavacamten
- UCB’s bimekizumab
- Bristol Myers Squibb’s/bluebird bio’s idecabtagene vicleucel (ide-cel)
- Ascendis Pharma’s TransCon hGH (lonapegsomatropin)
Sponsor: LGM Pharma
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show (https://dcat.org/MemberApplication.htm)
Support the show (https://dcat.org/MemberApplication.htm)
Drug delivery is important not only for ensuring bioavailability for therapeutic benefit but also for product differentiation and market success. DCAT Value Chain Insights highlights technology advances in drug delivery for injectable and solid-dosage drugs and other products from recent start-ups, partnering deals, and mergers and acquisitions. For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
Mergers and acquisitions
Partnering
Start-ups
New strategy/management
Sponsor: Vetter Pharma International GmbH
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show (https://dcat.org/MemberApplication.htm)
What have been the key developments in 2021 thus far in the CDMO market? In this podcast we take a look at the increasing participation by CDMOs in COVID-19 vaccine manufacturing and robust mergers and acquisition activity that have marked the first half of 2021. What are the implications, and what can be expected going forward? For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- CDMOs and COVID-19 vaccine manufacturing
- Potential implications of increased injectables capacity
- CDMO M&A remains robust
- Cell and gene therapies: a major source of CDMO M&A
- Private equity and CDMO M&A
- Largest deal thus far: Thermo Fisher Scientific/PPD
Sponsor: Vetter Pharma International GmbH
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show (https://dcat.org/MemberApplication.htm)
Support the show (https://dcat.org/MemberApplication.htm)
FDA Addresses Supply Constraints Due to COVID-19; Plus, Packaging Suppliers Expand
In this podcast we take a look at the FDA’s new guidance to facilitate changes to container-closure-system components due to supply constraints, plus updates from suppliers of materials used to deliver COVID-19 vaccines, treatments and other parenteral drugs. For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- FDA addresses supply constraints
- Suppliers increase production
Sponsor: Vetter Pharma International GmbH
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show (https://dcat.org/MemberApplication.htm)
Although the COVID-19 pandemic dominated the headlines in 2020, there were other key developments in 2020. In this year in review, we look at the other key developments in 2020, including new product approvals, noteworthy deals, and other developments making the news. For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
2020 in Review: The Top 10 Developments
-
Volume growth of pharmaceuticals declines globally.
-
New molecular entities approvals by FDA keeps pace with prior years.
-
The new AbbVie: AbbVie’s $63-Bn acquisition of Allergan.
-
Viatris launches as new company: Mylan plus Upjohn, Pfizer’s off-patent branded and generic established medicines business.
-
Gilead Sciences’ $21-Bn acquisition of Immunomedics
-
Danaher’s $21.4-Bn acquisition of GE Healthcare Life Sciences and launch of Cytiva.
-
Merck & Co.’s pending spin-off of women’s health, biosimilars & legacy products to form a new company.
-
Reshoring drug manufacturing gains policy momentum.
-
Some drug pricing reforms in the US move forward
-
Brexit uncertainty still looms.
Sponsor: Vetter Pharma International GmbH
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show (https://dcat.org/MemberApplication.htm)
In this podcast we feature an article about what and who is behind Viatris, the new company formed from the combination of Upjohn, Pfizer’s off-patent branded and generic established medicines business, and Mylan. For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- Rationale for the new company
- Inside the new Viatris: products
- Inside the new Viatris: manufacturing
- Inside Viatris: leadership, company structure, and cost-savings plan
Sponsor: LabVantage Solutions
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show (https://dcat.org/MemberApplication.htm)
In this podcast we feature an article that looks at solid dosage manufacturing in terms of CDMO growth rates and recent product trends. For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- New drug approvals and solid-dosage products
- CDMOs/CMOs: inside the numbers
- Recent facility acquisitions among solid-dose CDMOs/CMOs
- Other expansions
- Catalent
- Lonza
- Metrics Contract Services
- NextPharma
- Thermo Fisher Scientific
- LGM Pharma
- Frontida BioPharm
- Adare Pharmaceuticals
- CoreRx
- Velesco Pharma
- Upperton Pharma Solutions
Sponsor: Vetter Pharma International GmbH
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show (https://dcat.org/MemberApplication.htm)
In this podcast we feature a list of the Top 10 pharma CEOs to watch in 2020. For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- Pharma CEOs to watch in 2020
-
- Three-way tie: Pfizer, J&J, and AstraZeneca.
- Pfizer Chairman and CEO Albert Bourla
- J&J Chairman and CEO Alex Gorsky
- AstraZeneca CEO Pascal Soriot
-
- Moderna CEO Stéphane Bancel
-
- Gilead Sciences Chairman and CEO Daniel O’Day
-
- Regeneron Pharmaceuticals Co-Founder, President and CEO Leonard S. Schleifer
- 7 (tie). CureVac CEO Franz-Werner Haas and Novavax CEO and President Stanley C. Erck
-
- Seagen (formerly Seattle Genetics) President, CEO and Chairman Clay Siegall
-
- Genmab CEO Jan G. J. van de Winkel
Sponsor: LabVantage Solutions
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show (https://dcat.org/MemberApplication.htm)
Support the show (https://dcat.org/MemberApplication.htm)
In this podcast we feature an article that looks at some key upcoming developments from the pipelines of the large pharmaceutical companies for new drugs or existing drugs with new indications with blockbuster potential. For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- Inside Big Pharma’s pipeline
- AbbVie
- Amgen/AstraZeneca
- AstraZeneca
- Bristol-Myers Squibb
- Eli Lilly and Company
- GlaxoSmithKline
- Roche
Sponsor: Vetter Pharma International GmbH
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show (https://dcat.org/MemberApplication.htm)
Support the show (https://dcat.org/MemberApplication.htm)
In this podcast we feature a roundup of up expansions by CDMOs/CMOs and other suppliers in injectable drug development and manufacturing. For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- Injectable drugs and recent drug approvals
- Manufacturing expansions and technology advances
- A roundup of CDMO/CMO expansions thus far in 2020
- Vetter
- Catalent
- Grand River Aseptic Manufacturing
- CordenPharma
- Alcami
- Thermo Fisher Scientific
- Recipharm
- Samsung Biologics
- PCI Pharma Services
- WuXi Biologics
- Bushu Pharmaceuticals
- Evonik
- LSNE Contract Manufacturing
- Berkshire Sterile Manufacturing
- Integrity Bio
- Argonaut Manufacturing Services
- Suppliers of packaging materials and components for injectable drugs expand
- Corning
- Stevanato Group
- Schott
- West Pharmaceutical Services
Sponsor: Vetter Pharma International GmbH
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show (https://dcat.org/MemberApplication.htm)
Support the show (https://dcat.org/MemberApplication.htm)
In this podcast we feature an article that looks at the small molecules approved as new molecular entities thus far in 2020 and which have blockbuster potential. For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- Small-molecule new drug approvals thus far in 2020
- Small molecules and blockbuster potential
- Novo Nordisk’s Rybelsus
- Bristol-Myers Squibb’s Zeposia
- Novartis’ inclisiran
- Gilead Sciences’ filgotinib
- Akebia Therapeutics’, Mitsubishi Tanabe Pharma’s, and Otsuka Pharmaceutical’s vadadustat
- Biohaven Pharmaceuticals’ Nurtec
Sponsor: Dr. Reddy’s Laboratories
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show (https://dcat.org/MemberApplication.htm)
In this podcast we feature the top 10 deals thus far in 2020 and which pharma/biopharma companies are rising to the top. For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
-
Novartis’s $9.7-billion acquisition of The Medicines Company and Blackstone’s $2-billion investment in Alnylam Pharmaceuticals.
-
Daiichi Sankyo’s and AstraZeneca’s $6-billion ADC collaboration. Pairing
-
Gilead Sciences’ $4.9-billion acquisition of Forty Seven Inc.
-
Genmab’s $3.9-billion cancer antibody pact with AbbVie.
-
Sanofi’s pending $3.69-billion acquisition of Principia Biopharma.
-
Amgen’s $3.2-billion combined deals with BeiGene .
-
Astellas’s $3-billion acquisition of Audentes Therapeutics.
-
Sangamo Therapeutics’ $2.7-billion licensing pact with Biogen.
-
Merck & Co’s $2.7-billion acquisition of ArQule .
10 (Tie): Merck & Co.’s $2.5-billion research pacts with Taiho Pharmaceutical and Astex Pharmaceuticals, subsidiaries of Otsuka .
10 (Tie): Sanofi ’s $2.5-billion acquisition of Synthorx .
Sponsor: LabVantage Solutions
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show (https://dcat.org/MemberApplication.htm)
In this podcast we feature an article that outlines the FDA’s proposed pilot program for the evaluation of novel excipients and summarizes industry feedback on the review program. For a text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
Novel excipients and the FDA
FDA’s view of a possible novel excipient review pilot program
Industry feedback
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Sponsor: LabVantage Solutions
Support the show (https://dcat.org/MemberApplication.htm)
In this podcast we feature an article that looks at the policy debate to repatriate and increase domestic drug manufacturing in the US in light of the COVID-19 pandemic and pharmaceutical supply-chain vulnerabilities. For a text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- A plan for addressing supply-chain vulnerabilities in the US
- Legislative proposals in the US
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show (https://dcat.org/MemberApplication.htm)
In this podcast we feature an article that explores the future of digital medicines. For a text version of this article, visit dcatvci.org.
Key topics: (see Chapter Markers)
- Digital medicines and digital health
- Digital health and digital medicines: a market view
- Pharma industry and digital health and digital medicines
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show (https://dcat.org/MemberApplication.htm)
In this podcast we feature DCAT Value Chain Insights’ Top 10 Emerging Pharma Watch List based on recent high-value partnering deals. For a text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- Emerging pharma strength
- 1. Roivant Sciences
- 2. Sangamo Therapeutics
- 3. Silence Therapeutics
- 4. Innovent Biologics
- 5. Arcus Biosciences
- 6. MorphoSys
- 7. Evox Therapeutics
- 8. Accent Therapeutics
- 9. Enleofen Bio
-
- Sitryx
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show (https://dcat.org/MemberApplication.htm)
In this podcast we feature an article that looks at the near-term and long-term impact of the COVID-19 pandemic as biopharma companies re-access drug-development projects. For a text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- The CDMO industry in the wake of COVID-19
- Near-term outlook
- Medium-term could be challenging
- Longer-term implications
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show (https://dcat.org/MemberApplication.htm)
In this podcast, we round up key recent expansions in high-potency manufacturing by CDMOs and CMOs. For a text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- Expansions in high-potency manufacturing
- Lonza
- WuXi AppTec
- Seqens
- Cambrex
- Piramal Pharma Solutions
- CordenPharma
- Flamma
- Cerbios-Pharma
- Evonik
- AGC
- Novasep
- Ajinomoto Bio-Pharma Services
- BSP Pharmaceuticals
- PCI Pharma Services
- Sterling Pharma Solutions
- Heraeus
- Procos
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show (https://dcat.org/MemberApplication.htm)
In this podcast, we feature an article about a recent DCAT Benchmarking study, conducted prior to COVID-19, that provides insights on whether biopharma companies and their suppliers believe the deteriorating trade environment is a major threat, and what they are doing to confront the real and potential risks to their supply chains. For a text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- Examining trade-related risks
- Study's background
- Sources of supply-chain risk
- Awareness of supply-chain risk
- Managing supply-chain risks
- US market scenarios
- Vulnerable industry supply chains
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show (https://dcat.org/MemberApplication.htm)
In this podcast, we feature an article that examines the new AbbVie, including the key products and expanded manufacturing networking, resulting from its recent acquisition of Allergan. For a text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- Inside the deal
- Inside the new AbbVie
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show (https://dcat.org/MemberApplication.htm)
In this podcast, we feature an article about the Association for Accessible Medicines’ blueprint to facilitate a repatriation of pharma manufacturing to the US. For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- A plan for re-inventing the US pharma supply chains
- A proposal for increasing US-based manufacturing for high-priority medicines
- List of essential medicines and assessment of the supply chain
- Incentives for securing the US pharma supply chain
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show (https://dcat.org/MemberApplication.htm)
In this podcast, we outline the manufacturing strategies and alliances that are in play to develop and supply treatments and vaccines against COVID-19? For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- Inside the numbers: tracking potential treatments and vaccines
- Supply lines for potential COVID-19 drugs and vaccines
- The supply lines: vaccines
- Ramping up production for potential COVID-19 drugs
Sponsor: CordenPharma
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show (https://dcat.org/MemberApplication.htm)
In this podcast, we feature an article that examines the effect of COVID-19 on drug development, clinical trials, regulatory review, and new drug approvals. For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- Drug development and regulatory review
- FDA’s perspective
- New drug approvals thus far in 2020
- Clinical trials and COVID-19: where the impact resides
- Companies adjust clinical-trial research strategies
Sponsor: CordenPharma
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show (https://dcat.org/MemberApplication.htm)
In this podcast we feature DCAT Value Chain Insights’ Top 10 Watch List for Biologics and Biomanufacturing. For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- Vaccines: the race for a vaccine against the novel coronavirus.
- Vaccine manufacturing: technology and scale-up.
- Biologic-based antivirals against the novel coronavirus.
- Head of the class: the top-selling biologics.
- Biologics’ share of new drug approvals.
- Biosimilars: new market entrants.
- Biosimilars and interchangeability: the market impact.
- Cell and gene therapies: manufacturing investments.
- Advances in biomanufacturing.
- Live biotherapeutic products: a new opportunity.
Sponsor: CordenPharma
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show (https://dcat.org/MemberApplication.htm)
What measures are being taken by European Union authorities to mitigate potential shortages stemming from supply-chain and manufacturing disruptions? In this podcast we feature an article that outlines the guidance issued by EU authorities to provide flexibility in sourcing for crucial medicines for the treatment of COVID-19. For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- Providing regulatory flexibility for sourcing activities
- The exceptional change-management process
- Other measures in the EU to mitigate drug shortages
Sponsor: CordenPharma
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show (https://dcat.org/MemberApplication.htm)
What impact is COVID-19 having on pharmaceutical supply chains? In this podcast, we feature an article that reports on the concerns raised by industry groups, including reduced availability of international air transportation and increasing costs for shipping medicines into the US. For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- Industry groups weigh in on supply-chain concerns
- International air transportation availability and costs
- Repatriation of pharmaceutical manufacturing back to the US
- Potential supply disruptions of drugs identified as potential treatments against COVID-19
- Prescription refills
Sponsor: CordenPharma
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show (https://dcat.org/MemberApplication.htm)
In this podcast, we feature an article that looks at the Indian government’s $1.3-billion multi-year plan to increase domestic production of key starting materials and active pharmaceutical ingredients and its potential impact on global supply chains. For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- India and pharmaceuticals: short term
- India and pharmaceuticals: longer term
Sponsor: CordenPharma
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show (https://dcat.org/MemberApplication.htm)
What does the global nature of the pharmaceutical supply chain mean for US policy? In this podcast, we feature an article that looks at proposals from members of Congress and the federal government to incentivize domestic drug manufacturing in the US. For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- Global pharmaceutical supply chains
- Proposals for encouraging US-based pharmaceutical manufacturing
- Other legislative proposals
- Executive action
Sponsor: CordenPharma
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show (https://dcat.org/MemberApplication.htm)
What are the new blockbuster medicines to watch? In this podcast we feature an article that examines the eleven medicines projected to enter the market in 2020 and achieve blockbuster status by 2024, according to a recent analysis by Clarivate Analytics’ Cortellis Forecast Team. For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- Blockbuster watch: Big Pharma
- Novo Nordisk’s Rybelsus (semaglutide)
- AstraZeneca’s and Daiichi Sankyo’s Enhertu (fam-trastuzumab deruxtecan-nxki)
- Immunomedics’ sacituzumab govitecan
- Bristol-Myers Squibb’s liso-cel (or lisocabtagene maraleucel),
- Bristol-Myers Squibb’s ozanimod
- Novartis’ ofatumumab (subcutaneous)
- Novartis’ inclisiran
- Gilead Sciences’ filgotinib
- Akebia Therapeutics’, Mitsubishi Tanabe Pharma’s, and Otsuka Pharmaceutical’s vadadustat
- BioMarin Pharmaceutical’s Valrox
- Biohaven Pharmaceuticals’ rimegepant
Sponsor: CordenPharma
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show (https://dcat.org/MemberApplication.htm)
Over the past several years, orphan drugs have accounted for more than 40% of new drug approvals by the FDA. In this podcast, we showcase an article that explores whether they are producing the revenue gains pharma companies are seeking or if they are too niche? For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- Inside new drug approvals and drug-development trends for orphan drugs
- Inside the market for orphan drugs
- Market outlook for orphan drugs
- Orphan-drug NMEs and market penetration
Sponsor: CordenPharma
Links:
Subscribe to our e-newsletter at www.dcatvci.org
Follow us on Twitter @DCATvci
Support the show (https://dcat.org/MemberApplication.htm)
To what extent do emerging pharma companies contribute to the pharmaceutical industry’s pipeline and new product growth? In this podcast, we showcase an article examining a recent report by IQVIA that analyzes emerging bio pharma companies’ contribution to innovation. For the text version of this article visit dcatvci.org.
Key topics: (see Chapter Markers)
- Inside the numbers
- Inside emerging biopharma companies
- Emerging biopharma companies and larger companies
- Emerging biopharma companies and therapeutic focus
- Emerging biopharma companies and commercial products
Sponsor: CordenPharma
Links:
Subscribe to our e-newsletter at dcatvci.org
Follow us on Twitter @DCATvci
Support the show (https://dcat.org/MemberApplication.htm)
The conditions are favorable for another strong year of performance for CDMOs. In this podcast, we showcase an article written by Jim Miller, Consultant and Content Advisor at DCAT, that examines industry fundamentals and an outlook for pharma outsourcing in 2020. For the text version of this article go to dcatvci.org.
Key topics: (see Chapter Markers)
- Strong fundamentals but some risk
- Mergers and acquisitions: what may be ahead
- Big Pharma restructuring
- Upbeat outlook
Sponsor: CordonPharma
Links:
Subscribe to our e-newsletter at dcatvci.org
Follow us on Twitter @DCATvci
Support the show (https://dcat.org/MemberApplication.htm)